ImmunIC将参加四月份的科学和医学会议-动脉网

Immunic to Participate in Scientific and Medical Conferences in April

PR Newswire 等信源发布 2026-04-09 18:30



可切换为仅中文







NEW YORK

纽约

，

April 9, 2026

2026年4月9日

/PRNewswire/ --

Immunic

伊穆尼克

, Inc.

公司

(Nasdaq:

（纳斯达克：

IMUX

输入多路复用器

), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following scientific and medical conferences in April:

），一家处于后期阶段的生物技术公司，率先开发用于神经系统疾病的新型口服疗法，今天宣布了将参与以下四月份的科学和医学会议：

April 14-16:

4月14日至16日：

8th Annual Neuroimmunology Drug Development Summit.

第八届神经免疫学药物开发峰会。

Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will give a presentation highlighting lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), at this conference in Boston. The presentation will be available on the 'Events and Presentations' section of Immunic's website at: .

Immunic首席科学官Hella Kohlhof博士将在波士顿的这次会议上发表演讲，重点介绍其主导资产——核受体相关1（Nurr1）激活剂维多氟啶钙（IMU-838）。该演讲将在Immunic官网的“活动与演讲”部分提供。

https://ir.imux.com/events-and-presentations

。

Presentation Title:

演示标题：

Vidofludimus Calcium Uniquely Combines Direct Neuroprotective & Anti-inflammatory Properties for the Treatment of Multiple Sclerosis

Vidofludimus钙独特地结合了直接神经保护和抗炎特性，用于治疗多发性硬化症。

Presenting Author:

报告作者：

Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic

海拉·科尔霍夫博士，Immunic首席科学官

Session Title:

会话标题：

Beyond Microglia: Unlocking New Neuroimmune Targets To Drive Innovation In CNS Drug Discovery

超越小胶质细胞：解锁新的神经免疫靶点，推动中枢神经系统药物研发创新

Session Date:

会话日期：

Thursday, April 16, 2026

2026年4月16日，星期四

Session Time:

会话时间：

12:00 pm ET

中午12点（东部时间）

April 18-22:

4月18日至22日：

2026

American Academy of Neurology (AAN) Annual Meeting.

美国神经病学学会 (AAN) 年会。

Members of Immunic's management, medical and preclinical teams will attend this meeting in Chicago. The team will be available throughout the event at booth #3830.

Immunic的管理、医学和临床前团队成员将出席在芝加哥举行的这次会议。团队将在整个活动期间于3830号展位提供服务。

About Immunic, Inc.

关于Immunic公司

Immunic, Inc. (Nasdaq:

Immunic有限公司（纳斯达克：

IMUX

输入多路复用器

) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026.

）是一家处于后期阶段的生物技术公司，率先开发用于神经系统疾病的新型口服疗法。该公司的主要开发项目——维多氟啶钙（IMU-838），目前正处于治疗复发缓解型多发性硬化症的第三阶段临床试验，预计将在2026年底前获得关键数据。

It has already shown therapeutic activity in phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH).

它在复发缓解型多发性硬化症、进展型多发性硬化症和其他疾病的二期临床试验中已显示出治疗活性。Vidofludimus钙通过其作为第一类核受体相关1（Nurr1）激活剂的机制，结合了神经保护作用，并通过选择性抑制二氢乳清酸脱氢酶（DHODH）发挥额外的抗炎和抗病毒作用。

The company's development pipeline also includes earlier-stage programs, including IMU-856 and IMU-381, aimed at building a broader therapeutics platform addressing neurodegenerative, chronic inflammatory, and autoimmune-related diseases. For further information, please visit: .

公司的研发管线还包括一些早期项目，包括IMU-856和IMU-381，旨在构建一个更广泛的治疗平台，针对神经退行性、慢性炎症和自身免疫相关疾病。欲了解更多信息，请访问：。

www.imux.com

。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性陈述的谨慎声明

This press release contains 'forward-looking statements' that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements.

本新闻稿包含“前瞻性声明”，这些声明涉及1995年《私人证券诉讼改革法案》所提供的安全港条款下的重大风险和不确定性。本新闻稿中除历史事实陈述之外的所有声明，包括关于战略、未来运营、未来财务状况、未来收入、预计费用、现金及现金跑道的充足性、临床试验的预期时间、进展与结果、前景、管理层的计划和目标的声明，均为前瞻性声明。

Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in scientific and medical conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements.

此类陈述的示例包括但不限于与管理层和员工参与科学和医学会议相关的陈述。Immunic可能无法实际实现这些前瞻性陈述中披露的计划、执行意图或满足预期或预测，您不应过度依赖这些前瞻性陈述。

Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be pred.

此类声明基于管理层的当前预期，并涉及重大风险和不确定性。实际结果和业绩可能因多种因素而与前瞻性声明中预计的内容存在重大差异，这些因素包括但不限于：通货膨胀加剧、关税和宏观经济趋势、俄乌冲突及中东冲突对计划中和正在进行的临床试验的影响、与预测未来现金使用和或有未来负债及业务运营所需储备相关联的风险和不确定性、是否有足够的财务及其他资源来满足业务目标和运营需求、早期临床前研究和临床试验的结果可能无法预测等事实。

www.sec.gov

or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release..

或 ir.imux.com/sec-filings。本新闻稿中包含的任何前瞻性声明仅截至本新闻稿发布之日。Immunic 不承担更新这些前瞻性声明以反映其作出之后发生的事件或情况的意图或义务。Immunic 明确否认对基于本新闻稿全部或部分内容采取或未采取的任何行动承担任何责任。

Contact Information

联系方式

Immunic, Inc.

Immunic有限公司

Jessica Breu

杰西卡·布劳

Vice President Investor Relations and Communications

投资者关系与传播副总裁

+49 89 2080 477 09

[email protected]

电子邮件地址